OCT 05, 2016 10:30 AM PDT

Immunotherapy of Cancer Using Genetically-Enhanced T Cells

Speaker
  • Assistant Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania, Associate Director, Toxicology Laboratory, University of Pennsylvania Perelman Scho
    Biography
      Dr. Milone received his M.D. and Ph.D. in experimental pathology in 1999 from Rutgers-New Jersey Medical School (formerly the University of Medicine and Dentistry of New Jersey). After an Internship in Internal Medicine at the Hospital of the University of Pennsylvania, he completed post-graduate medical training in Clinical Pathology, Transfusion Medicine and Laboratory Toxicology. Following clinical training, Dr. Milone pursued post-doctoral research training in cancer immunology and adoptive immunotherapy with Dr. Carl June at the University of Pennsylvania where he performed basic research to develop CTL019, a genetically modified T cell therapy for B-cell leukemia and lymphoma that has been licensed by Novartis and undergoing early phase clinical testing. He is currently an Assistant Professor of Pathology and Laboratory Medicine at the University of Pennsylvania School of Medicine. At present, Dr. Milone's laboratory is focused on T cell biology and the development of new techniques for culturing and genetically modifying T lymphocytes for adoptive immunotherapy of cancer.

    Abstract

    The immune system possesses significant cytotoxic potential. Stimulating natural immunity through vaccination has shown promising effects in some cancers; however, a number of barriers limit the efficacy of the natural immune system including tolerance to self-antigens and immunodeficiency associated with cancer and associated chemotherapy.  Adoptive immunotherapy using T-cells that are genetically modified to express an artificial receptor that combines the antigen specificity of an antibody with the signal transduction machinery of the T-cell receptor in a single chimeric antigen receptor (CAR) hold significant promise for overcoming many of the barriers to anti-cancer immunity.  This talk will describe the clinical applications of CARs that target CD19, a molecule expressed by normal B-cells and cells in a range of B-cell malignancies including acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) as well as a CARs targeting BCMA for multiple myeloma and mesothelin for solid malignancies. Toxicity related to this cell therapy that includes a cytokine release syndrome and long term B-cell aplasia will also be discussed.
     


    Show Resources
    You May Also Like
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    APR 07, 2020 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    MAY 08, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    FEB 19, 2020 11:00 AM PST
    C.E. CREDITS
    FEB 19, 2020 11:00 AM PST
    DATE: February 19, 2020TIME: 11:00am PST, 2:00pm EST...
    Loading Comments...
    Show Resources